Enzalutamide

• Description :

  Enzalutamide (MDV3100) is an androgen receptor (AR) antagonist with an IC50 of 36 nM in LNCaP prostate cells. Enzalutamide is an autophagy activator[1][2].

• CAS Number :

  [915087-33-1]

• Product Name Alternative :

  MDV3100

• UNSPSC :

  12352005

• Hazard Statement :

  H315, H319, H335

• Target :

  Androgen Receptor; Autophagy

• Type :

  Reference compound

• Related Pathways :

  Autophagy; Vitamin D Related/Nuclear Receptor

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/Enzalutamide.html

• Purity :

  99.97

• Solubility :

  DMSO : ≥ 50 mg/mL

• Smiles :

  S=C(N(C(C1(C)C)=O)C2=CC=C(C#N)C(C(F)(F)F)=C2)N1C3=CC(F)=C(C(NC)=O)C=C3

• Molecular Formula :

  C21H16F4N4O2S

• Molecular Weight :

  464.44

• Precautions :

  H315, H319, H335

• References & Citations :

  [1]Tran C, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science, 2009, 324 (5928), 787-790.|[2]Scher HI, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet, 2010, 375 (9724), 1437-1446.|[3]Guerrero J, et al. Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer. Prostate. 2013 Sep;73 (12) :1291-305.|[4]Kim TH, et al. Pharmacokinetics of enzalutamide, an anti-prostate cancer drug, in rats. Arch Pharm Res. 2015 Nov;38 (11) :2076-82.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched